Ultragenyx Pharmaceutical Inc. (LON:0LIF)

Ultragenyx Pharmaceutical Statistics

Total Valuation

LON:0LIF has a market cap or net worth of GBP 1.60 billion. The enterprise value is 1.99 billion.

Market Cap	1.60B
Enterprise Value	1.99B

Important Dates

The last earnings date was Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	96.43M
Shares Outstanding	n/a
Shares Change (YoY)	+8.95%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	3.49%
Owned by Institutions (%)	98.71%
Float	92.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.20
PB Ratio	-29.46
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.65
EV / Sales	3.96
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.67

Financial Position

The company has a current ratio of 2.48

Current Ratio	2.48
Quick Ratio	2.19
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-2.65
Interest Coverage	-8.63

Financial Efficiency

Return on equity (ROE) is -608.47% and return on invested capital (ROIC) is -28.45%.

Return on Equity (ROE)	-608.47%
Return on Assets (ROA)	-22.03%
Return on Invested Capital (ROIC)	-28.45%
Return on Capital Employed (ROCE)	-46.60%
Weighted Average Cost of Capital (WACC)	4.85%
Revenue Per Employee	364,726
Profits Per Employee	-311,616
Employee Count	1,371
Asset Turnover	0.44
Inventory Turnover	17.71

Taxes

In the past 12 months, LON:0LIF has paid 2.97 million in taxes.

Income Tax	2.97M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.65% in the last 52 weeks. The beta is 0.21, so LON:0LIF's price volatility has been lower than the market average.

Beta (5Y)	0.21
52-Week Price Change	-39.65%
50-Day Moving Average	23.00
200-Day Moving Average	30.14
Relative Strength Index (RSI)	46.29
Average Volume (20 Days)	1,675

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.45

Income Statement

In the last 12 months, LON:0LIF had revenue of GBP 500.04 million and -427.23 million in losses. Loss per share was -4.33.

Revenue	500.04M
Gross Profit	-138.20M
Operating Income	-397.51M
Pretax Income	-424.25M
Net Income	-427.23M
EBITDA	-371.50M
EBIT	-397.51M
Loss Per Share	-4.33

Balance Sheet

The company has 505.24 million in cash and 930.24 million in debt, with a net cash position of -382.65 million.

Cash & Cash Equivalents	505.24M
Total Debt	930.24M
Net Cash	-382.65M
Net Cash Per Share	n/a
Equity (Book Value)	-54.24M
Book Value Per Share	-0.62
Working Capital	421.28M

Cash Flow

In the last 12 months, operating cash flow was -346.24 million and capital expenditures -4.46 million, giving a free cash flow of -350.70 million.

Operating Cash Flow	-346.24M
Capital Expenditures	-4.46M
Free Cash Flow	-350.70M
FCF Per Share	n/a

Margins

Gross margin is -27.64%, with operating and profit margins of -79.49% and -85.44%.

Gross Margin	-27.64%
Operating Margin	-79.49%
Pretax Margin	-84.84%
Profit Margin	-85.44%
EBITDA Margin	-74.29%
EBIT Margin	-79.49%
FCF Margin	n/a

Dividends & Yields

LON:0LIF does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.95%
Shareholder Yield	-8.95%
Earnings Yield	-26.74%
FCF Yield	-21.95%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0LIF has an Altman Z-Score of -3.17 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.17
Piotroski F-Score	4